• In May 2026, Walmart Inc. announced that Teladoc Health’s virtual urgent care, dermatology, and nutrition services are now available on Walmart’s Better Care Services platform for US$89 per cash-pay visit, with prescriptions eligible for same-day or free Walmart+ delivery in many locations.
• This expansion, building on the earlier integration of BetterHelp mental health services, plugs Teladoc deeper into Walmart’s extensive retail health ecosystem and broadens access to insured and cash-pay virtual care through a trusted national brand.
• Next, we’ll examine how this deeper Walmart integration, especially the US$89 cash-pay visits, may influence Teladoc Health’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Teladoc Health Investment Narrative Recap

To own Teladoc Health, you need to believe virtual care can grow into a mainstream front door to healthcare, and that Teladoc can translate its broad platform into improving margins despite ongoing net losses. The Walmart Better Care integration looks directionally helpful, but on its own it does not immediately change the key near term catalyst of progress toward profitability or the central risk that BetterHelp and chronic care margins remain under pressure.

The most relevant recent development alongside the Walmart news is Teladoc’s January 2026 upgrade of its 24/7 Care service, which expanded treatable conditions and specialist input. Together, those enhancements and Walmart’s US$89 cash-pay visits highlight Teladoc’s push toward higher visit volumes and more flexible pricing, an important test of whether a visit-based model can support earnings improvement without deepening the existing margin and cost headwinds.

Yet behind this expanding Walmart presence, investors should also weigh the risk that rising compliance and cybersecurity costs could quietly compress margins and materially affect shareholder outcomes...

Teladoc Health's narrative projects $2.6 billion revenue and $164.1 million earnings by 2029. This implies fairly flat yearly revenue growth and an earnings increase of about $364 million from -$200.3 million today.

Uncover how Teladoc Health's forecasts yield a $7.12 fair value, in line with its current price.

Exploring Other Perspectives

While consensus sees modest revenue growth, the most pessimistic analysts were assuming revenues could slip about 1.1 percent a year and margins stay negative, reminding you that views on Teladoc’s post Walmart path can differ sharply and that it is worth comparing several scenarios before deciding what you believe.

Explore 4 other fair value estimates on Teladoc Health - why the stock might be worth just $7.12!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Teladoc Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teladoc Health's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.